Truman Medical Centers

Summary

Truman Medical Centers is a medical facility located in Kansas City, Missouri. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Truman Medical Centers is involved with conducting 209 clinical trials across 424 conditions. There are 20 research doctors associated with this hospital, such as Jun Zhang, Chao H. Huang, Anwaar Saeed, and Gary C. Doolittle.

Top PIs

Clinical Trials running at Truman Medical Centers

Bladder Cancer

Breast Cancer

Bladder Carcinoma

Breast cancer

Lung Cancer

Kidney Cancer

Esophageal cancer

Pancreatic Cancer

Pancreatic Carcinoma

Cancer

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria